Pierre Rossignon

Pierre Rossignon

Auto-generated profile, based on publicly available information

Pierre Rossignon

Department of Cardiology, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg; Department of Intensive Care, Hôpital Universitaire de Bruxelles-Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2024 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
PRPierre Rossignon
Pierre Rossignon
LNLe Diep Kieu Nguyen
Le Diep Kieu Nguyen
PBPetra Boegner
Petra Boegner
JKJade Ku
Jade Ku
AHAntoine Herpain
Antoine Herpain
The increasing incidence of urothelial carcinoma, coupled with advancements in its therapeutic landscape, has resulted in improved survival rates for patients. This, in turn, has led to a growing population of patients requiring specialized oncological care, with Enfortumab vedotin (EV) emerging as a pivotal treatment for metastatic urothelial carcinoma. While EV is associated with hyperglycemia, ketoacidosis is exceedingly rare. To the best of our knowledge, the link between EV and hemophagocytic lymphohistiocytosis (HLH) has not yet been explored. A 56‑year‑old patient diagnosed with metastatic urothelial carcinoma underwent EV treatment as a third‑line treatment after progression following treatment with cisplatin/gemcitabine and pembrolizumab. Notably, after receiving two doses of EV, the patient exhibited refractory insulin resistance, leading to ketoacidosis. Subsequently, HLH emerged, necessitating a treatment regimen involving dexamethasone and etoposide. Despite intensive efforts, the patient experienced septic shock, resulting in death. The present case report highlights refractory insulin resistance and ketoacidosis, followed by reactive HLH, in the context of EV therapy. The limited literature on these complications demonstrates the need for further research to improve the understanding of the underlying mechanisms. With growing evidence of the efficacy of EV and evolving survival rates in urothelial carcinoma, healthcare professionals must remain vigilant for potential adverse effects, ensuring early recognition and optimal patient care.

13 July 2023 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
PRPierre Rossignon
Pierre Rossignon
KAKenza El Alaoui
Kenza El Alaoui
ASAlain Soupart
Alain Soupart
Spontaneous periodic hypothermia (SPH) is an exceptionally rare condition characterised by paroxysmal episodes of spontaneous hypothermia. While commonly associated with Shapiro syndrome, which includes SPH, hyperhidrosis and agenesis of the corpus callosum, there are also cases of SPH that do not exhibit these defining characteristics, known as ‘Shapiro syndrome variant'. These variants may present with diverse brain imaging findings but no agenesis of the corpus callosum, suggesting different potential aetiologies. Notably, the association of SPH with epilepsy has only been reported in a few cases, and confirming epileptic activity in the context of SPH remains a challenge. In line with this, our report presents two exceptional cases of SPH without significant brain malformation, where we successfully confirmed the presence of epilepsy. The confirmation of epilepsy in these cases is particularly noteworthy, as it adds to the limited documentation of SPH cases with confirmed epilepsy. These findings contribute valuable insights into the association between SPH and epilepsy, enhancing our understanding of this rare condition. Our report also addresses the broader clinical presentations and the physiopathological mechanisms of SPH. By providing comprehensive insights into these aspects, we aim to advance the existing literature and improve our understanding of SPH and its association with epilepsy.

13 December 2023 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
PRP. Rossignon
P. Rossignon
FGF. Grandjean
F. Grandjean
ACA. Claessens
A. Claessens
NWN. Weynants
N. Weynants
Acquired coagulopathies resulting from factor X deficiency are rare and typically associated with amyloidosis or plasma cell dyscrasia. Factor X plays a pivotal role in the coagulation cascade, converting prothrombin into thrombin and facilitating the formation of fibrinogen and thrombus. While its occurrence following common infections is extremely rare, isolated cases have been documented. We present a rare case of bleeding diathesis in a patient with community-acquired pneumonia, where prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT) led to the diagnosis of an infectious-triggered acquired circulating inhibitor targeting factor X. Prompt treatment with methylprednisolone effectively controlled the inhibitor without recurrence. This case report provides insights into the diagnostic strategies, differential algorithm, and therapeutic approaches for managing this rare coagulopathy.

18 December 2024 in Netherlands Heart Journal
Verified
Journal Article
Open access
PDF file
PRPierre Rossignon
Pierre Rossignon
RTRiad Tajildin
Riad Tajildin
EFEdith Famdie
Edith Famdie

26 February 2024 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
PRPierre Rossignon
Pierre Rossignon
SMSofia Morra
Sofia Morra
QHQuentin de Hemptinne
Quentin de Hemptinne
DCDidier de Cannière
Didier de Cannière
PUPhilippe Unger
Philippe Unger
Background: Percutaneous transvenous mitral commissurotomy (PTMC) is the first-line therapy of clinically significant rheumatic mitral stenosis. While the procedure is generally safe, new onset or aggravation of mitral regurgitation (MR) may occur, mainly due to commissural splitting and, less frequently, to leaflet tear and chordal rupture. Papillary muscle rupture (PMR) is exceedingly rare in this setting. Case summary: A 74-year-old woman with a history of aortic valve replacement and prior rheumatic mitral commissurotomy presented for worsening exercise intolerance and exertional dyspnoea. Transthoracic echocardiography showed a mean pressure gradient of 10 mmHg and a mitral valve area of 1.0 cm², consistent with clinically significant mitral stenosis. Subsequent PTMC was complicated by anterolateral PMR. However, the resulting MR was unexpectedly only of mild-to-moderate severity. Because of residual mitral stenosis and persisting symptoms, surgical mechanical mitral valve replacement and tricuspid annuloplasty were performed 6 weeks after PTMC. Papillary muscle rupture was confirmed during surgery. Discussion: We herein describe the occurrence of PMR induced by PTMC; the resulting MR was unexpectedly of mild-to-moderate severity, as a result of extensive rheumatic lesions limiting valve mobility. This case challenges the dogma according to which PMR invariably leads to severe MR. This might not be necessarily the case when it occurs following PTMC.

19 November 2024 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
PRPierre Rossignon
Pierre Rossignon
ACAbouzar Chaudhry
Abouzar Chaudhry
MAMounia Alloum
Mounia Alloum
TAThomas Antoine-Moussiaux
Thomas Antoine-Moussiaux
ASAlain Soupart
Alain Soupart
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of euvolemic hyponatremia, resulting from non-osmotic release of antidiuretic hormone (ADH). SIADH is frequently associated with neurological conditions, including traumatic brain injury (TBI). TBI-associated SIADH usually develops within days to weeks and resolves within a few weeks. We present the case of a 74-year-old man who, after a fall resulting in TBI, initially had normal sodium levels. Fifteen days later, he developed moderate-to-severe hyponatremia (120 mmol/l) and significant neurological symptoms. Treatment with urea effectively normalized his sodium levels and resolved symptoms. However, recurrent hyponatremia persisted for over six months whenever urea treatment was discontinued. This unusual duration of TBI-associated SIADH underscores the importance of long-term follow-up in the management of post-traumatic hyponatremia.